Open Access

Toll-like receptor 2 downregulates the cholesterol efflux by activating the nuclear factor‑κB pathway in macrophages and may be a potential therapeutic target for the prevention of atherosclerosis

  • Authors:
    • Yongqiang Li
    • Shuxin Shen
    • Shoukun Ding
    • Lixia Wang
  • View Affiliations

  • Published online on: October 31, 2017     https://doi.org/10.3892/etm.2017.5404
  • Pages:198-204
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views
0

Abstract

Atherosclerosis is a chronic inflammatory disease, which is triggered by lipid retention. Toll‑like receptor 2 (TLR2) is a novel target for therapeutic intervention in atherosclerosis. In addition, nuclear factor‑κB (NF‑κB) serves important roles in stress response and inflammation. The present study investigated whether TLR2 is involved in the activation of cholesterol efflux in macrophages by regulating the NF‑κB pathway. The human monocytic THP‑1 cell line and murine macrophage RAW264.7 cell line were treated with 50 µg/ml oxidized low‑density lipoprotein (ox‑LDL) for 48 h in order to obtain macrophage foam cells. The cholesterol efflux of the cell lines under exogenous TLR2 treatment was assessed by liquid scintillation counting. Furthermore, the protein and mRNA expression levels of ATP binding cassette transporter A1 (ABCA1), ABCG1 and scavenger receptor B1 (SR‑B1) were examined by western blot and quantitative polymerase chain reaction assays, respectively. To detect the effect of NF‑κB on cholesterol efflux, the cells were divided into three groups, including the control, 10 ng/ml lipopolysaccharides (LPS; 24 h) and 10 ng/ml LPS + 50 µM pyrrolidinedithiocarbamate (PDTC; 24 h) groups. The results indicated that ox‑LDL induced foam cell formation in the THP‑1 and RAW264.7 cells, while TLR2 significantly decreased the cholesterol efflux in dose‑ and time‑dependent manners. Accordingly, TLR2 reduced ABCA1, ABCG1 and SR‑B1 expression at the transcriptional and translational levels in a dose‑dependent manner. In addition, application of PDTC (an NF‑κB specific inhibitor) markedly suppressed the LPS‑induced downregulation of cholesterol efflux. These data revealed that TLR2 may be involved in the activation of cholesterol efflux in macrophages by regulating the NF‑κB signaling pathway.

Related Articles

Journal Cover

January 2018
Volume 15 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

2016 Impact Factor: 1.261
Ranked #50/128 Medicine Research and Experimental
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Li, Y., Shen, S., Ding, S., & Wang, L. (2018). Toll-like receptor 2 downregulates the cholesterol efflux by activating the nuclear factor‑κB pathway in macrophages and may be a potential therapeutic target for the prevention of atherosclerosis. Experimental and Therapeutic Medicine, 15, 198-204. https://doi.org/10.3892/etm.2017.5404
MLA
Li, Y., Shen, S., Ding, S., Wang, L."Toll-like receptor 2 downregulates the cholesterol efflux by activating the nuclear factor‑κB pathway in macrophages and may be a potential therapeutic target for the prevention of atherosclerosis". Experimental and Therapeutic Medicine 15.1 (2018): 198-204.
Chicago
Li, Y., Shen, S., Ding, S., Wang, L."Toll-like receptor 2 downregulates the cholesterol efflux by activating the nuclear factor‑κB pathway in macrophages and may be a potential therapeutic target for the prevention of atherosclerosis". Experimental and Therapeutic Medicine 15, no. 1 (2018): 198-204. https://doi.org/10.3892/etm.2017.5404